The downgrade by a prominent analyst like Mitchel Penn from Oppenheimer can lead to a negative perception among investors, potentially causing a short-term decline in SAR's stock price. The reduction in the price target further emphasizes a less optimistic outlook on the company's valuation, which could influence investor sentiment and stock performance negatively in the short term.